

04-30-07

STJ-

Attorney Docket No. 5470-401

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Stafford et al.
Application No.: 10/573,131
Filed: April 18, 2006

Confirmation No.: 4529
Group Art Unit: 1634
Examiner: J. Sitton

For: *METHODS AND COMPOSITIONS FOR THE CORRELATION OF SINGLE
NUCLEOTIDE POLYMORPHISMS IN THE VITAMIN K EPOXIDE REDUCTASE
GENE AND WARFARIN DOSAGE*

Date: April 27, 2007

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §1.97(b)**

Sir:

Attached is a list of documents, together with a copy of any listed foreign patent document and/or non-patent literature. A copy of any listed U.S. patent and/or U.S. patent application publication is not provided herewith in accordance with the amendment by the U.S. Patent and Trademark Office to 37 C.F.R. § 1.98(a)(2)(ii) effective October 21, 2004.

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. § 1.97(b), within three months of the filing date of the above-referenced application or before the mailing of a first Office Action on the merits, whichever event occurs last. Therefore, no fee is believed due. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. § 1.56 and Section 609 of the MPEP.

Myers Bigel Sibley & Sajovec, P.A.
P. O. Box 37428
Raleigh, North Carolina 27627
Telephone: (919) 854-1400
Facsimile: (919) 854-1401
Customer No. 20792

Respectfully submitted,


Mary L. Miller
Mary L. Miller
Registration No. 39,303

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10

"Express Mail" mailing label number: EV854928722US ; Date of Deposit: April 27, 2007

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Evelyn Casey
Evelyn Casey

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 1 of 2				Complete if Known	
		Application Number		10/573,131	
		Filing Date		April 18, 2006	
		First Named Inventor		Darrel W. Stafford	
		Group Art Unit		1634	
		Examiner Name		Sitton	
		Attorney Docket No.		5470-401	

U.S. PATENTS AND PATENT PUBLICATIONS					
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
		US-			

U.S. PATENT APPLICATIONS				
Examiner Initials*	Cite No.	U.S. Serial No.	Name of Applicant of Cited Document	Date of Filing of Cited Document MM-DD-YYYY
		US-		

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation
		Office	Number	Kind Code (if known)			

OTHER NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	1.	Absher et al. "Patient-Specific Factors Predictive of Warfarin Dosage Requirements" <i>Ann Pharmacother</i> 36 (10):1512-1517 (2002)	
	2.	Chenhsu et al. "Long-Term Treatment with Warfarin in Chinese Population" <i>Ann Pharmacother</i> 34 (12):1395-1401 (2000)	
	3.	Devlin et al. "A Comparison of Linkage Disequilibrium Measures for Fine-Scale Mapping" <i>Genomics</i> 29 (2):311-322 (1995)	
	4.	Durrin et al. "Vitamin D receptor 3'-untranslated region polymorphisms: lack of effect on mRNA stability" <i>Biochimica et Biophysica Acta</i> 1453 (3):311-320 (1999)	
	5.	Fang et al. "National Trends in Antiarrhythmic and Antithrombotic Medication Use in Atrial Fibrillation" <i>Arch Intern Med</i> 164 (1):55-60 (2004)	
	6.	Himly et al. "Defective Vaccinia Virus as a Biologically Safe Tool for the Overproduction of Recombinant Human Secretory Proteins" <i>Protein Expression and Purification</i> 14 (3):317-326 (1998)	
	7.	Hirsh et al. "Antithrombotic therapy in deep vein thrombosis and pulmonary embolism" <i>American Heart Journal</i> 123 (4, Pt. 2):1115-1122 (1992)	
	8.	Jones et al. "A Cellular DNA-Binding Protein That Activates Eukaryotic Transcription and DNA Replication" <i>Cell</i> 48 (1):79-89 (1987)	
	9.	Kirchheiner et al. "Clinical consequences of cytochrome P450 2C9 polymorphisms" <i>Clinical Pharmacology & Therapeutics</i> 77 (1):1-16 (2005)	
	10.	Landefeld et al. "Anticoagulant-Related Bleeding: Clinical Epidemiology, Prediction, and Prevention" <i>The American Journal of Medicine</i> 95 (3):315-328 (1993)	
	11.	Loebstein et al. "Interindividual variability in sensitivity to warfarin - Nature or nurture?" <i>Clinical Pharmacology & Therapeutics</i> 70 (2):159-164 (2001)	
	12.	Mountford et al. "Internal ribosome entry sites and dicistronic RNAs in mammalian transgenesis" <i>Trends Genet.</i> 11 (5):179-184 (1995)	
	13.	Pechlaner et al. "A New Case of Combined Deficiency of Vitamin K Dependent Coagulation Factors" <i>Thrombosis and Haemostasis</i> 68 (5):617 (1992)	
	14.	Pennisi, Elizabeth "A Closer Look at SNPs Suggests Difficulties" <i>Science</i> 281 (5834):1787-1789 (1998)	
	15.	Stanley et al. "Identification of a vitamin K-dependent carboxylase in the venom duct of a <i>Conus</i> snail" <i>FEBS Letters</i> 407 (1):85-88 (1997)	
	16.	Suttie et al. "Mechanisms of action of vitamin K: synthesis of gamma-carboxyglutamic acid" <i>CRC Crit Rev. Biochem</i> 8 (2):191-223 (1980)	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/573,131
		Filing Date	April 18, 2006
		First Named Inventor	Darrel W. Stafford
		Group Art Unit	1634
Examiner Name	Sitton		
Sheet	2 of 2	Attorney Docket No.	5470-401

OTHER NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	17.	Wallin et al. "Purification of Warfarin-Sensitive Vitamin K Epoxide Reductase" <i>Methods in Enzymology</i> 282 :395-408 (1997)	
	18.	Wu et al. "Characterization of the γ -Glutamyl Carboxylase" <i>Thrombosis and Haemostasis</i> 78 (1):599-604 (1997)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.